Stockholm, Sweden, May 9, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting 2019. The following resolutions were adopted:
Annual report and result
The meeting adopted the income statement and balance sheet for the Company and for the Group according to submitted accounting documents and resolved, in accordance with the Board of Directors’ proposal, that profits of SEK 899,721,875, are allocated with SEK 132,089,978 distributed to shareholders as dividend and residual earnings of SEK 767,631,898 carried forward.
The Board’s proposal amounts to a dividend of SEK 1.50 per share. The record day for the right to receive dividend was resolved to be May 13, 2019.
Discharge from liability
The Annual General Meeting granted the Board of Directors and the managing director discharge from liability for the financial year 2018.
Board members and fees
The ordinary board members Wenche Rolfsen, Ivar Verner, Hans Ekelund, Pär Gellerfors, Lars Lannfelt, Eugen Steiner and Mikael Smedeby were re-elected by the Annual General Meeting. Ewa Björling was elected new member of the board. Wenche Rolfsen and Ivar Verner were re-elected as Chairman and Deputy Chairman, respectively.
The meeting adopted the Nomination Committee’s proposal for board fees and other fees, with the following distribution: SEK 500,000 to the Chairman of the Board, SEK 300,000 to the Deputy Chairman, SEK 250,000 to each of the other board members not employed by the Company, SEK 100,000 to the Chairman of the Audit Committee, SEK 60,000 to each of the other members of the Audit Committee not employed by the Company, SEK 60,000 to the Chairman of the Remuneration Committee, and SEK 40,000 to each of the other members of the Remuneration Committee not employed by the Company.
Auditor and auditor fees
The meeting resolved, in accordance with the Nomination Committee’s proposal, to appoint the registered auditing firm Grant Thornton Sweden AB to be the auditor of BioArctic AB for the period until the end of the next Annual General Meeting. Mia Rutenius will continue as chief auditor. Fees to the auditor shall be paid upon approved account.
Remuneration to senior executives
The Annual General Meeting approved the Board of Directors’ proposal for resolution concerning guidelines for remuneration to senior executives.
Nomination Committee
The Nomination Committee’s proposal for principles for and the establishment of the
Nomination Committee in preparation for the Annual General Meeting 2020 were approved by the Annual General Meeting.
Employee warrant program
The Annual General Meeting approved the Board of Directors’ proposal for resolution concerning an employee warrant program for the Company’s management, researchers and other staff, on a directed issue of warrants and approved the transfer of warrants or shares in the Company to the participants in the employee warrant program.
The employee warrant program 2019/2028 shall include not more than 1,000,000 warrants. To enable the Company’s delivery of shares under the employee warrant program 2019/2028, the AGM decided on a directed issue of a maximum of 1,000,000 warrants.
The maximum dilution effect of the employee warrant program 2019/2028 is estimated to be a maximum of 1.1 percent of the share capital and 0.5 percent of the votes in the Company (calculated on the number of existing shares in the Company), provided full exercise of all employee warrants.
For more information, please contact:
Jan Mattsson, CFO, BioArctic AB
Telephone: +46 8 695 69 30
Mobile: +46 70 352 27 72
E-mail: jan.mattsson@bioarctic.se
This information was submitted for publication at 19:00 p.m. CET on May 9, 2019.
About BioArctic
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). www.bioarctic.com